National Anti-vivisection Society

 

National Antivisection Society

Response to the statement of the EU Scientific Steering Committee: References

Posted: 13 July 2007

1 Feinberg, M.B. and Moore, J.P (2002) ‘AIDS vaccine models: Challenging challenge viruses’ Nature Medicine, vol.8.3.
2 Zbinden, G & Flury-Roversi, M. (1981) Archives of Toxicology vol.47, 77-99
3 Haigwood, N.L (2004) ‘Predictive value of Primate Models for AIDS’ AIDS Reviews, vol 6, 187-198
4 Moneim A Fadali, MD, FACS, Cardiovascular and Thoracic Surgeon, in ‘Animal Experimentation - A Harvest of Shame’, Hidden Springs Press, USA
5 O’Neill, ‘A room with a view for captive primates: Issues, Goals, Related Research and Strategies In Housing, Care and Psychological Well-Being of
Captive and Laboratory Primates’, 1989
6 Zhong, J, et al (2005) ‘Robust hepatitis C virus infection in vitro’ PNAS 102 (26): 9294-9299
7 Sattabongkot, J., et al (2006) ‘Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocyte stages of the malaria
parasites plasmodium falciparum and P. vivax’, The American Society of Tropical Medicine and Hygiene 74(5) :708-715
8 Macete, E. V., et al (2007) Evaluation of two formulations of adjuvented RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic
region of Mozambique: a Phase I/IIb randomized double-blind bridging trial Trials 8:11
9 Mayor, A., et al (2007) ‘The epidemiology of malaria in adults in a rural area of southern Mozambique’, Malaria Journal, 6 (3) doi:10.1186/1475-2875-6-3
10 Clark, I. A., et al (2006) ‘Human malaria disease: a consequence of inflammatory cytokine release’, Malaria Journal 5:85
11 Animal Experiments at Inveresk (2005) report based on internal documents, ADI
12 Wee, E.G.T, Patel, S McMichael, A.J. Hanke, T.(2002) ‘A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multispecific
T cell responses in rhesus macaques’ Journal of General Virology vol 83, 75-80
13 Yao, et al (2005) ‘gC1qR expression in chimpanzees with resolved and chronic infection: Potential role of HCV core/gC1qR-mediated T cell suppression
in the outcome of HCV infection’, Journal of Virology 346: 324-337
14 Ruprecht R.M. et al, (1999) ‘Oral Transmission of Primate Lentiviruses’ The Journal of Infectious Diseases179(suppl)s408-412
15 Prescott, M.J. and Jennings. M. (2004) ‘Ethical and Welfare Implications of the acquisition and Transport of non-human primates for use in research and
testing’, ATLA 32, supplement1323-327
16 Honess, P.E. et al (2003) ‘A study of behavioural responses of non-human primates to air transport and re-housing’ Laboratory Animals 38,119-132
17 RSPCA Caged and Cruel (Supplement to Counting the Cost report), 2002
18 The Stationery Office, Statistics of Scientific Procedures on Living Animals, 2003
19 Report of the House of Lords Select Committee on the use of Animals in Scientific Procedures, (2002), The Stationery Office
20 Bailey J., Knight A. and Balcombe J. (2005), ‘The future of teratology research is in vitro’, Biogenic Amines 19(2): 97-145
21 Villinger F et al (2001), ‘Cloning, sequencing, and homology analysis of nonhuman primate Fas/Fas-ligand and co-stimulatory molecules’,
Immunogenetics 53:315-328 and Bhogal N & Combes R (2006), ‘TGN1412: Time to change the paradigm for the testing of new pharmaceuticals’, ATLA
34:225-239, and Kenter MJH & Cohen AF (2006) ‘Establishing risk of human experimentation with drugs: lessons from TGN1412’, The Lancet 368:1387-
1391
22 Smith, JM et al. Journal of Anatomy 2001; 198: 537-554
23 Tattersal, I. Scientific American, January 1993: 90-97
24 Mishkin, M & Appenzeller, T. The Anatomy of Memory. A Scientific American Report, 1987: 62-71
25 Scientific American Editorial. March 2000: 11-12
26 St George-Hyslopp & Westaway, D Nature, 8 July 1999; 400: 116-117
27 Br J Hosp Medicine; 1990, 43: 327
28 MRMC. Perspectives on Medical Research (1991), 3: 35-46
29 Br J Pharmacology, 1992. Vol. 107, Proceedings suppl. 300P
30 Alzheimer’s Research Trust (website); 3 January 2006, report by Prof Martin Knapp of the London School of Economics and Political Science.
31 Hanke, T (2006) ‘Lessons from TGN1412’ The Lancet, 368, 1569-1570
32 Palfreyman, M. G., Charles, V. and Blander, J. (2002), The importance of using human-based models in gene and drug discovery, Drug Discovery World,
33–40.)
33 Levine R. (1978) Pharmacology: Drug Actions and Reactions, (Little, Brown & Co
34 Detweiler DK (1993), as cited in conference reports. ATLA 21: 106-107
35 Baldwin, A. and Bekoff, M (2007) ‘Too stressed to work’, New Scientist 2606: p24
36 Dash, S. et al (1997) Transfection of hepG2 cells with infectious hepatitis C virus genome. American journal of pathology 151(2) 363-373
37 Sheehy, P. et al (2007) “In vitro replication models for the hepatitis C virus.” Journal of Viral Hepatitis, 14: 2-10
38 Jolicoeur, P., (1991). Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. The FASEB Journal,
Vol: 5, pp: 2398-2405. 1991
39 Cohen, J. (2007) ‘NIH to end chimp breeding for research’ Science, 316, 1265
40 Nielsen R. et al. (2005), A Scan for positively selected genes in the genomes of humans and chimpanzees, PLoS Biology, June; 3(6): e 170
41 http://www..niaid.nih.gov/news/newsreleases/2001/hivmacrophage.htm NIH Scientists Highlight Role of Macrophages in HIV Infection National Institute
of Allergy and Infectious Diseases (NIAID) Monday, Jan. 1, 2001
42 Nuffield Council of Bioethics: The ethics of research involving animals (2005). Latimer Trend & Company Ltd, UK
43 Varki, A. (2007) ‘The uncertain future of research Chimpanzees’ Science, 315, 1493
44 Feinberg, M. B. and Moore, J. P. (2002) AIDS vaccine models: Challenging challenge viruses. Nature medicine 8 (3): 207-210
45 Haigwood, N. L (2004) Predictive Value of Primate Models for AIDS. AIDS Reviews 6:187-198
46 Esclante, A.A. Freeland, D.E. Collins, W.E. and Lal, A.A. (1998) ‘The evolution of primate malaria parasites based on the gene encoding cytochrome b
from the linear mitochondrial genome’ Proceedings of the National Academy of Sciences of the United States of America”, 95, 8124-8129
47 Martin, M. J., Rayner, J.C., Gagneux, P., Barnwell, J.W and Varki, A (2005) Evolution of human-chimpanzee differences in malariasuceptability:
Relationship to human genetic loss of N-glycolylneuraminic acid. PNAS 102(36): 12819-12824
48 Taylor Bennett, B. Abee, C.R. & Henrickson,R. eds. (1995) Non human primates in biomedical research – biology and management. Chapter 8,
Vandeburgh, J.L.
49 Sattabongkot, J., et al (2006) Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocyte stages of the malaria
parasites plasmodium falciparum and P. vivax. The American Society of Tropical Medicine and Hygiene 74(5) :708-715
50 Langermans, J.A.M., et al (2006) Preclinical evaluation of a chimeric malaria vaccine candidate in montanide ISA 720
51 Carvalho, L. H., Fontes, C. J.F. and Krettli (1999), Cellular responses to Plasmodium falciparum major surface antigens and their relationship to human
activities associated with malaria transmission, American Journal of Tropical Medicine and Hygine60(4): 674-679
52 Roll Back Malaria info sheet : Roll Back Malaria is a global partnership initiated by WHO, UNDP, UNICEF and the World Bank in 1998. It seeks to work
with governments, other development agencies, NGOs, and private sector companies to reduce the human and socio-economic costs of malaria
http://rbm.who.int/cmc_upload/0/000/015/368/RBMInfosheet_5.htm
53 Langermans, J. A. M., et al (2001) ‘Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Myobacterium tuberculosis infection in highly
related macaque species: Implications for primate models in tuberculosis vaccine research’, PNAS 98 (20): 11497-11502
54 Ling Lin, P., et al (2006) ‘Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques’ Infectious Immun. July; 74(7): 3790–3803
55 Capuano.S.V.III, et al (2003) ‘Experimental Mycobacterium tuberculosis Infection of Cynomolgus Macaques Closely Resembles the Various
Manifestations of Human M. tuberculosis Infection’ Infect Immun. October; 71(10): 5831–5844
56 Sheehy, P., et al (2007) ‘In vitro replication models for the hepatitis C virus’, Journal of Viral Hepatitis, 14: 2-10
57 Lanford, R.E. Bigger, C, Bassett, S. and Klimpel, G. (2001) ‘The Chimpanzee Model of Hepatitis C virus infections’ ILAR, 42,2, 117-126
58 Institute of Medicine, 1995, Review of Fialuridine (FIAU) Clinical Trials, Washington DC: National Academic Press
http://books.nap.edu/openbook.php?isbn=0309052793&page=250
59 Behan, P: ‘Have we got it horribly wrong?’ New Scientist 16 Nov 2002, No 2369
60 Ransohoff, R (2006) EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis, Trends in Immunology: 27(4) 167-168
61 Sriram, S and Steiner, I (2005) ‘Experimental Allergic Encephalomyleitis: A Misleading Model of Multiple Sclerosis’, American Neurological Association:
58(6):939-945
62 Prat, A., et al (2005) ‘Kinin B1 receptor expression on multiple sclerosis mononuclear cells’ Archives of Neurology 62: 795-800
63 Frohman, E. M et al (2005) ‘Theraputic considerations for disease progression in multiple sclerosis’Archives of Neurology 62 :1519-1530
64 The Scientist (1990) 23 July :20-24
65 Notkins, AL (1979) Scientific American, 241: 62-73
66 Mandrup-Poulsen, T. (1998) ‘Recent advances Diabetes’ BMJ, 316, 1221-1225
67 Tal, M.G. et al (2004) ‘Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of
streptozotocin’ Radiology, 230, 163-168
68 Pyke, D.A Clinics in Endocrinology and Metabolism 6:285-303
69 Forslund, K (1997) ‘Similarities and differences between animal species and man with special reference to rheumatoid arthritis and diabetes mellitus’
ATLA 25, 183-185
70 Lemon R.N. and Griffiths J. (2005) ‘Comparing the function of the corticospinal system in different species: Organizational differences for motor
specialization?’ Muscle & Nerve 32 (3): 261-279
71 Crick, F & Jones, E. Nature 1993; 361: 109-110
72 News-Media.Net: New MS drug withdrawn from the market, 8 March 2005 http://www.news-medical.net/?id=8303
73 t’Hart, B.A. Smith, P. Amor, S, Strijkers, G.J. and Blezer, E.L.A. (2006) ‘MRI-guided immunotherapy development for multiple sclerosis in a primate’ DDT,
vol.11, number 1/2, January
74 Sattabongkot, J., et al (2006) ‘Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocyte stages of the malaria
parasites plasmodium falciparum and P. vivax. The American Society of Tropical Medicine and Hygiene 74(5) :708-715
75 Zhong, J., et al (2005) Robust hepatitis C virus infection in vitro. PNAS 102 (26): 9294-9299
76 Coecke S. et al. (2006) ‘The value of alternative testing for neurotoxicity in the context of regulatory needs’ Environmental Toxicology and Pharmacology
21: 153-167
77 Editorial, 19 October 1985, The Lancet
78 Ichinose, L Y. (1995), Chimpanzees in AIDS Research in ‘Poor Model Man: Experimenting on Chimpanzees’, Proceedings of Conference on the Use of
Chimpanzees in Biomedical Research, PACE p598-606
79 Kaufman, S. (1995) Difficulties with Animal Models in ‘Poor Model Man: Experimenting on Chimpanzees’, Proceedings of Conference on the Use of
Chimpanzees in Biomedical Research, PACE p595
80 Hu, S., (2005). Non-Human Primate Models for AIDS Vaccine Research. Curr Drug Targets Infect Disorder 5 (2):193-201
81 Pennisi, E. Science, 12 April 2002; 233-235
82 Nielsen R. et al. (2005), A Scan for positively selected genes in the genomes of humans and chimpanzees, PLoS Biology, June; 3(6): e 170
83 Perel, P., et al (2006) Comparison of treatment effects between animal experiments and clinical trials: systematic review, BMJ,
doi:10.1136/bmj.39048.407928.BE).
84 . (Hackam, D.G. (2007) ‘Translating animal research into clinical benefit’ BMJ, 334,136-164
85 Bates, D.W (1998) ‘Drugs and adverse drug reactions – how worried should we be?’ JAMA 279, 15, 1216-1217
86 Perel, M., et al (2004) ‘Adverse drug reactions as cause of admission to hospital:prospective analysis of 18 820 patients’ BMJ, 329, 15-19
87 Bhattacharya, S (2005) ‘Up to 140,000 heart attacks linked to Vioxx’ New Scientist http:http://www.newscientist.com/article.ns?id=dn6918&print=true
88 Mayor, S. (2005) ‘Rofecoxib caused excess heart disease’ BMJ 330, 212
89 Gosline, A (2004) ‘Vioxx heart risks apparent for years’ New Scientist http:http://www.newscientist.com/article.ns?id=dn6627&print=true
90 Bhattacharya, S (2005) ‘Up to 140,000 heart attacks linked to Vioxx’ New Scientist http:http://www.newscientist.com/article.ns?id=dn6918&print=true
91 Preston, KL & Bigelow, GE (1991) Behavioural Pharmacology 2: 293-313
92 Sriram, S and Steiner, I (2005) ‘Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis’, American Neurological Association:
58(6):939-945
93 Venters, G.A. (2001) ‘New Variant Creutzfeldt-Jakob disease: epidemic that never was’, BMJ 323, 858-861
94 (Coghlan, A. (2001) ‘Thinking the unthinkable’ New Scientist 2313, 12-13)
95 Lasmezas, et al (2005) ‘Risk of oral infection with bovine spongiform encephalopathy agent in primates’ The Lancet, 365, 781-783
96 Coghlan, A. (2001) ‘Thinking the unthinkable’ New Scientist 2313, 12-13
97 Spencer, M.D. Knight, R.S.G. Will, R.G (2002) First hundred cases of variant Creutzfeldt-Jakob disease; retrospective case note review of early
psychiatric and neurological features
98 http://www.vetmed.ucdavis.edu/Animal_Alternatives/databaseapproach.html
99 Guerra-Neira, A., et al (2006) ‘Plasmodium diversity in non-malaria individuals from the Bioko Island in equatorial Guinea’, International Journal of Health
Geographics 5 :27
100 Ironside, J.W. (1999) nvCJD; exploring the limits of our understanding Biologist, 46 (4)

© National Anti-Vivisection Society